Category
1 Chemical carcinogenesis and radiation carcinogenesis
2 Experimental animal models and genetically-engineered animals
3 Virus, infection, inflammation and cancer
4 Oncogenes and tumor-suppressor genes
5 Signal transduction and gene expression
6 DNA replication/cell cycle/genomic instability
7 Cancer genome/genetics
8 Cell death/immortalization
9 Epigenetics
10 Invasion and metastasis
11 Characteristics of cancer cells
12 Cancer immunity
13 Growth factors/cytokines/hormones
14 Cancer basic, diagnosis and treatment
15 Diagnosis
16 Molecular-targeting therapy
17 Chemotherapy and endocrine therapy
18 Evaluation and prediction of pharmacological effects
19 Radiation therapy
20 Cell therapy and regeneration medicine
*If your abstract is categorized to a clinical trial or case report/series that includes tumor agnostic treatment, please select a sub-category of “14. Cancer basic, diagnosis and treatment”.
1 Chemical carcinogenesis and radiation carcinogenesis
| 1-1 | Activation and metabolism of carcinogens |
|---|---|
| 1-2 | Detection and assessment of carcinogens |
| 1-3 | DNA damage |
| 1-4 | Process of carcinogenesis |
| 1-5 | Nitric oxide/reactive oxygen |
| 1-6 | Genotoxins and nongenotoxins |
| 1-7 | Experimental cell culture systems |
| 1-8 | Radiation and electromagnetic wave carcinogenesis |
| 1-9 | Others |
2 Experimental animal models and genetically-engineered animals
| 2-1 | Gene-manipulated animal models |
|---|---|
| 2-2 | Animal model for carcinogenesis |
| 2-3 | Patient-derived experimental model |
| 2-4 | Others |
3 Virus, infection, inflammation and cancer
| 3-1 | EBV |
|---|---|
| 3-2 | HPV |
| 3-3 | HBV |
| 3-4 | HCV |
| 3-5 | HTLV-1 |
| 3-6 | HHV-8 |
| 3-7 | H.pylori |
| 3-8 | Other viruses/bacteria |
| 3-9 | Intestinal bacteria/microbiome |
| 3-10 | Inflammation and cancer |
| 3-11 | Others |
4 Oncogenes and tumor-suppressor genes
| 4-1 | ras family genes |
|---|---|
| 4-2 | p53-related genes |
| 4-3 | Rb/p16-related genes |
| 4-4 | Wnt signaling-related genes |
| 4-5 | Chromosomal translocation-related genes |
| 4-6 | Other oncogenes/tumor-suppressor genes |
| 4-7 | Novel oncogenes/tumor-suppressor genes |
| 4-8 | Others |
5 Signal transduction and gene expression
| 5-1 | 5-1. Proliferation/differentiation |
|---|---|
| 5-2 | Signal transduction |
| 5-3 | Transcriptional regulation |
| 5-4 | Translational regulation |
| 5-5 | RNA engineering |
| 5-6 | ncRNA・microRNA |
| 5-7 | Single cell analysis |
| 5-7 | Others |
6 DNA replication/cell cycle/genomic instability
| 6-1 | Cell cycle/checkpoint |
|---|---|
| 6-2 | DNA replication |
| 6-3 | DNA repair |
| 6-4 | Genetic instability |
| 6-5 | Others |
7 Cancer genome/genetics
| 7-1 | Genomic analysis |
|---|---|
| 7-2 | Clonal evolution |
| 7-3 | Genomic medicine/precision medicine |
| 7-4 | NGS |
| 7-5 | Genome editing |
| 7-6 | Chromosomal translocation/gene rearrangement |
| 7-7 | Copy number analysis |
| 7-8 | Familial tumor and target genes |
| 7-9 | Carcinogenic sensitivity-related genes (SNPs) |
| 7-10 | Others |
8 Cell death/immortalization
| 8-1 | Cell death |
|---|---|
| 8-2 | Telomere/senescence/immnortalization |
| 8-3 | Others |
9 Epigenetics
| 9-1 | DNA methylation |
|---|---|
| 9-2 | Histone modification |
| 9-3 | Chromatin structure |
| 9-4 | Others |
10 Invasion and metastasis
| 10-1 | Cell adhesion/invasion |
|---|---|
| 10-2 | Extracellular matrices and proteases |
| 10-3 | Metastasis-associated genes |
| 10-4 | Angiogenesis |
| 10-5 | Diagnosis of metastasis |
| 10-6 | Metastasis inhibition |
| 10-7 | Metastasis models |
| 10-8 | EMT (epithelial-mesenchymal transition) |
| 10-9 | Others |
11 Characteristics of cancer cells
| 11-1 | Cancer stem cellｓ |
|---|---|
| 11-2 | Cell differentiation |
| 11-3 | Tumor heterogeneity |
| 11-4 | Cell-to-cell interaction/adhesion molecules |
| 11-5 | Cell lines |
| 11-6 | Organoid |
| 11-7 | Carbohydrate chains and glycosyltransferases |
| 11-8 | Extracellular vesicles/Exosome |
| 11-9 | Metabolism / Metabolome |
| 11-10 | Phase separation |
| 11-11 | Others |
12 Cancer immunity
| 12-1 | Innate immunity |
|---|---|
| 12-2 | Dendritic cells/antigen-presenting cells |
| 12-3 | Tumor antigens |
| 12-4 | Antitumor effector cells and their induction |
| 12-5 | Immune checkpoint inhibitors |
| 12-6 | Cell therapy/CAR-T |
| 12-7 | Antibody therapy |
| 12-8 | Other immunotherapies |
| 12-9 | Others |
13 Growth factors/cytokines/hormones
| 13-1 | Growth- and differentiation-regulating factors |
|---|---|
| 13-2 | Growth factor receptors |
| 13-3 | Hormones |
| 13-4 | Cytokines |
| 13-5 | TGF-b/Smad |
| 13-6 | Others |
14 Cancer basic, diagnosis and treatment
| 14-1 | Gastric cancer |
|---|---|
| 14-2 | Esophageal cancer |
| 14-3 | Colorectal cancer |
| 14-4 | GIST |
| 14-5 | Liver cancer |
| 14-6 | Carcinoma of the biliary tract |
| 14-7 | Pancreatic cancer |
| 14-8 | Lung cancer |
| 14-9 | Breast cancer |
| 14-10 | Uterine cancer |
| 14-11 | Ovarian cancer |
| 14-12 | Hematopoietic malignancy |
| 14-13 | Renal cell cancer |
| 14-14 | Bladder cancer |
| 14-15 | Prostatic cancer |
| 14-16 | Testicular cancer |
| 14-17 | Brain tumor |
| 14-18 | Primary bone tumor |
| 14-19 | Soft tissue sarcoma |
| 14-20 | Head and neck cancer |
| 14-21 | Endocrine cancer |
| 14-22 | Skin cancer |
| 14-23 | Childhood cancer/AYA |
| 14-24 | Other organs |
| 14-25 | Tumor agnositic treatment |
15 Diagnosis
| 15-1 | Pathological diagnosis |
|---|---|
| 15-2 | Pathological analysis |
| 15-3 | Diagnostic imaging/cancer imaging |
| 15-4 | Diagnosis by tumor markers and biomarkers |
| 15-5 | Genomic diagnostics/Panel sequencing |
| 15-6 | Diagnosis by expression analysis (mRNA, protein) |
| 15-7 | Novel diagnostic technology |
| 15-8 | Liquid biopsy |
| 15-9 | Artificial intelligence based diagnostics |
| 15-10 | Others |
16 Molecular-targeting therapy
| 16-1 | Signal transduction inhibitors/kinase inhibitors |
|---|---|
| 16-2 | Angiogenesis inhibitors/antimetastatic drugs |
| 16-3 | Cell cycle inhibitors (CDK inhibitors etc.) |
| 16-4 | Epigenetic drugs |
| 16-5 | Proteolysis (proteasome inhibitors/PROTAC) |
| 16-6 | Engineered antibodies (ADC etc.) |
| 16-7 | Others |
17 Chemotherapy and endocrine therapy
| 17-1 | Natural anticancer compounds |
|---|---|
| 17-2 | Synthetic anticancer compounds |
| 17-3 | DNA-damaging drug (Platinum compounds/Topoisomerase inhibitors etc.) |
| 17-4 | Antimetabolites |
| 17-5 | Antimicrotubular drugs (taxane/alkaloids etc.) |
| 17-6 | Anticancer drug resistance |
| 17-7 | Anticancer drug and cell death |
| 17-8 | Endocrine therapy |
| 17-9 | Differentiation-inducing therapy |
| 17-10 | Drug delivery system |
| 17-11 | Combinational therapy/adjuvant therapy |
| 17-12 | Others |
18 Evaluation and prediction of pharmacological effects
| 18-1 | Drug sensitivity/drug resistance-relating factors/gene expression analysis |
|---|---|
| 18-2 | Pharmacokinetics/pharmacodynamics (PK/PD) |
| 18-3 | Pharmacogenomics/toxicogenomics (SNPs, transcriptome, proteome) |
| 18-4 | Sensitivity test |
| 18-5 | Clinical trial |
| 18-6 | Translational research |
| 18-7 | Biobank |
| 18-8 | Others |
19 Radiation therapy
| 19-1 | Radiation and particle ray therapy |
|---|---|
| 19-2 | Radiation hazard/protection |
| 19-3 | Radiosensitivity |
| 19-4 | Efficacy enhancement |
| 19-5 | Hyperthermia |
| 19-6 | Others |
20 Cell therapy and regeneration medicine
| 20-1 | Stem cells |
|---|---|
| 20-2 | Regenerative medicine |
| 20-3 | Cell therapy of allograft |
| 20-4 | Others |
21 Gene therapy
| 21-1 | Generation and modification of vectors |
|---|---|
| 21-2 | Immunogenetic therapy |
| 21-3 | Oncogene/tumor-suppressor gene therapy |
| 21-4 | Suicide gene therapy |
| 21-5 | Nucleic acid therapeutics (including DDS) |
| 21-6 | Others |
22 Medical care of progressive cancer
| 22-1 | Psychooncology |
|---|---|
| 22-2 | Palliative treatment and care |
| 22-3 | Others |
23 Cancer prevention/chemoprevention
| 23-1 | Mechanism of cacinogenesis inhibition |
|---|---|
| 23-2 | Synthetic compounds |
| 23-3 | Natural products |
| 23-4 | Dietary/alimentary factors |
| 23-5 | Others |
24 Epidemiology
| 24-1 | Environmental factors (life habits etc.)/infectious exposure |
|---|---|
| 24-2 | Cancer prone syndromes/molecular epidemiology |
| 24-3 | Cohort study |
| 24-4 | Descriptive epidemiology/cancer registration |
| 24-5 | Cancer screening |
| 24-6 | Others |
25 Information/informatics
| 25-1 | Bioinfomatics |
|---|---|
| 25-2 | Big Data/Real World Data analysis |
| 25-3 | Management and analysis of cancer patients' data |
| 25-4 | Mathmatical modeling and simulation |
| 25-5 | Real World Evidence |
| 25-6 | Others |
26 Cancer and society
| 26-1 | Informed consent |
|---|---|
| 26-2 | Bioethics |
| 26-3 | Social movement against cancer |
| 26-4 | Smoking and drinking alcohol |
| 26-5 | Others |